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Although the incidence of breast cancer in the United States is higher in Caucasian women compared with African American
women, African-American patients have more aggressive disease as characterized by a higher percentage of triple-negative breast
cancers (TNBCs), high-grade tumors, and a higher mortality rate. PKCα is a biomarker associated with endocrine resistance and
poor prognosis and ERβ is emerging as a protective biomarker. Immunohistochemical analysis of ERβ and PKCα expression was
performed on 198 formalin-ﬁxed paraﬃn-embedded primary inﬁltrating ductal carcinomas from 105 African-American and 93
Caucasian patients. PKCα is positively correlated with TNBC in patients of both races and with high tumor grade in African-
American patients. Patients with TNBC express less nuclear ERβ compared with all other subtypes. We ﬁnd no diﬀerence in
frequencyorintensityofPKCαorERβ expressionbetweenAfrican-AmericanandCaucasianpatients.PKCαandERβ arediscussed
as potential therapeutic targets for the treatment of patients with TNBC.
1.Introduction
Although African American women have a lower incidence
of breast cancer than Caucasians, repeated studies have
shown that they suﬀer from more aggressive disease char-
acterized by diagnosis at an earlier age, later stage, higher
grade, and greater mortality [1–4]. While socioeconomic
factors contribute in part to this disparity in survival, they
do not account for all diﬀerences noted between these two
racial groups [3, 5, 6]. In particular, premenopausal African
American women present with a higher incidence of triple-
negative breast cancer (TNBC), a molecular subtype that
has limited targeted therapeutic options [3, 7]. Current
investigations are focused upon the identiﬁcation of new
therapeutic targets speciﬁc to the aggressive TNBC form
of breast cancers found more frequently in young African
American women and the development of more eﬀective
treatment modalities.
One potential biomarker contributing to the aggressive
nature of this disease in African American women is protein
kinase Cα (PKCα). PKC is a serine/threonine protein kinase
family of enzymes comprised of at least 12 isozymes that
regulate numerous cellular functions [8]. PKCα in particular
is involved in cell migration, apoptosis, diﬀerentiation, and
proliferation and plays a critical role in several disease
processes including cancer [9]. Overexpression of PKCα is
a marker of poor prognosis of breast cancers and is asso-
ciated with antiestrogen resistance, ERα-negative tumors,
and tumor aggressiveness [10–13]. Therefore, diﬀerential
expression of PKCα may underpin the observed racial
disparity in breast cancer and may be a potential therapeutic
target.2 International Journal of Breast Cancer
Although the clinical signiﬁcance of estrogen receptor
β (ERβ) in breast cancer is not yet ﬁrmly established,
diﬀerential expression of ERβ in breast cancers between
racial groups may provide further insight [14]. Recent
reports suggest ERβ isoform expression and subcellular
localization may correlate with endocrine response and
breast cancer outcome [15–18]. When coexpressed with
ERα,E R β appears to dampen the proliferative program
of ERα bound to estradiol and is generally considered to
be antiproliferative [19, 20]. However, understanding the
eﬀects of ERβ is complicated by the fact that several ERβ
isoforms exist, named ERβ 1–5 [21], and they have diﬀerent
implications in breast cancer development and progression.
While most studies conclude that ERβ confers a good
prognosis [16] and is predictive of response to tamoxifen
[22], others report association with more aggressive disease
and decreased overall survival [15, 23]. The accumulated
evidencethusfarindicatesthatalthoughERβexpressionmay
predict good prognosis, the expression in relation to breast
cancer subtypes and subcellular localization may inﬂuence
the eﬀect upon prognosis.
Since African American patients have more aggressive
disease and lower overall survival than Caucasian patients,
we tested the hypothesis that breast cancers from African
American patients have higher PKCα expression and lower
nuclear ERβ expression and/or higher cytoplasmic ERβ
expression. We analyzed 198 primary invasive ductal car-
cinomas from African American and Caucasian patients
for expression of PKCα and ERβ to determine whether
diﬀerential expression of PKCα and/or localization of ERβ
diﬀered in breast cancers from African American and
Caucasian women.
2.MaterialsandMethods
2.1. Patient Population. PKCα and ERβ expression was
determined by immunohistochemical (IHC) staining of 198
formalin-ﬁxed, paraﬃn-embedded primary inﬁltrating duc-
tal carcinomas from 105 African American and 93 Caucasian
patients from the Department of Pathology, Rush University
Medical Center. Complete clinicopathological characteristics
wereobtained fromthepathologyreportsandthenumberof
evaluable patients for each characteristic is given in Table 1.
ThisstudywasapprovedbytheInstitutionalReviewBoardat
Rush University Medical Center and the University of Illinois
at Chicago. All specimens were obtained retrospectively and
posed minimal risk; therefore informed consent was waived.
2.2. Immunohistochemical Staining for PKCα and ERβ. IHC
was performed on 5μM sections of formalin-ﬁxed paraﬃn-
embedded tissue with the Ventana Benchmark automated
staining platform using the iView DAB detection kit accord-
ing to company protocol using CC1 Standard antigen
retrieval. The PKCα antibody (rabbit polyclonal, Santa Cruz
Biotechnology, sc-208) was previously validated [11]a n d
used at a dilution of 1:200 and incubated at 37◦Cf o r3 0
minutes.TheERβmousemonoclonalantibody14C8(Novus
Biologicals Inc., Littleton, CO) was previously validated [24]
and used at a 1:100 dilution and incubated for 30min
with HRP-rabbit Envision. This ERβ monoclonal antibody
recognizes all isoforms of ERβ known to be expressed in
breast cancer. Frequency and intensity of PKCα and ERβ
staining of all tumor cells on each slide were scored on a
scale of 0 to 4 without knowledge of clinical patient data.
Frequency of positive staining in less than 1% of tumor cells
wasscoredas0,1%–10%as1,11%to-35%as2,36%–70%as
3,andover70%as4.Acompositescoreisalsoreportedbased
on the Allred scoring system which is a sum of the frequency
and intensity scores yielding numerical values from 0 to 8
[25].
2.3. Statistical Analysis. We analyzed the expression of ERβ
and PKCα by comparing them with prognostic factors
such as age, tumor grade, subtypes, and race. Chi-square
tests were used for testing association between race and
prognostics factors. For univariate analysis, nonparametric
tests were conducted for nonnormal data. Wilcoxon Rank
Sum test was performed for two groups’ comparisons and
Kruskal-Wallistestwasperformedformorethantwogroups’
comparisons. Median, minimum, and maximum along with
P values were reported. For multivariate analysis, to take into
account prognostic factor eﬀects, general linear regression
was conducted. The interaction eﬀects of race by prognostic
factors were examined. P values were reported based on the
type III sum of squares. P value < 0.05 was considered to
be statistically signiﬁcant. Freq, UNIVARIATE, NPAR1WAY,
and GLM procedures in SAS version 9.2 (Cary, NC) were
used in these analyses.
3. Results
3.1. PKCα and ERβ Expression in Tumors from African Ameri-
can and Caucasian Breast Cancer Patients. Since PKCα over-
expression and ERβ expression and localization are reported
to be associated with more aggressive breast cancers, we
ﬁrst asked whether these markers are diﬀerentially expressed
based on race. Upon examination of breast cancers from 93
Caucasian and 105 African American patients, we evaluated
both frequency and intensity of PKCα and ERβ immunos-
taining in addition to subcellular localization of ERβ.C a s e s
exhibiting both high and low frequency and intensity
of PKCα and ERβ were evident including both nuclear
and cytoplasmic ERβ localization (Figures 1(a) and 1(b)).
Examination of the total patient population (Table 1)
revealed that 78% of all patients were positive for PKCα
cytoplasmic staining. When patients were stratiﬁed by race,
76% of tumors from Caucasian patients and 79% of African
American patients stained positively for PKCα. There was
no statistical diﬀerence in the incidence of PKCα expression
between races. Sixty-nine percent of patients stained positive
for ERβ including nuclear and/or cytoplasmic staining. Of
these ERβ positive cases, 57% exhibited only nuclear ERβ
staining, 20% only cytoplasmic staining, and 23% both
nuclear and cytoplasmic staining. When stratiﬁed by race,
there is no statistical diﬀerence in the incidence of ERβ
expression. As anticipated, there is a statistically signiﬁcantInternational Journal of Breast Cancer 3
Table 1: Clinicopathological characteristics of 198 inﬁltrating ductal carcinomas.
Caucasian African American Total
P value∗
N (%) N (%) N (%)
PKCα+ 71 (76) 83 (79) 154 (78)
0.648 PKCα− 22 (24) 22 (21) 44 (22)
ERα+ 63 (68) 55 (52) 118 (60)
0.028∗∗
ERα− 30 (32) 50 (48) 80 (40)
ERβ+ 65 (70) 72 (69) 137 (69)
0.847 ERβ− 28 (30) 33 (31) 61 (31)
ERβ+ (nuc + cyto) 11 (17) 21 (29) 32 (23)
ERβ+ (nuc) 41 (63) 37 (51) 78 (57) 0.221
ERβ+ (cyto) 13 (20) 14 (19) 27 (20)
ERα+/ERβ+ 49 (53) 40 (38) 89 (45)
0.108 ERα+/ERβ− 14 (15) 15 (14) 29 (15)
ERα−/ERβ+ 16 (17) 32 (30) 48 (24)
ERα−/ERβ− 14 (15) 18 (17) 32 (16)
Subtype#
Luminal A 32 (35) 26 (26) 58 (30)
Luminal B 30 (33) 29 (28) 59 (31) 0.205
Her2+ 13 (14) 18 (18) 31 (16)
TNBC 16 (18) 29 (28) 45 (23)
Grade†
1 6 (13) 6 (8) 12 (10)
2 21 (46) 21 (29) 42 (35) 0.068
3 19 (41) 46 (63) 65 (55)
Lymph node+ 28 (35) 52 (58) 80 (47)
0.0024∗∗
Lymph node− 53 (65) 38 (42) 91 (53)
Tumor size 2.17 (1.47) 2.97 (1.87) 2.60 (1.73)
0.0007∗∗
Mean (SD)
Age
<50 28 (30) 45 (43) 73 (37)
0.064 ≥50 65 (70) 60 (57) 125 (63)
∗All P values were calculated using the Chi-square test. ∗∗P<0.05; #Five patients categorized as ER−/PR+/Her2− were not assigned to a subtype category
(3 African American, 2 Caucasian patients).
†Tumor grade was available on 46/93 Caucasian patients and 73/105 African American patients.
diﬀerence in ERα expression between races reﬂecting the
higher proportion of ERα-negative tumors in the African
American patient population. We also observed larger
tumors and more lymph node positive cases in the African
American population. When the intensity and frequency
of PKCα and ERβ was compared by race, there was no
diﬀerence in IHC staining between breast cancers from
African American and Caucasian patients (Tables 2(a) and
2(b)).
3.2. PKCα Expression in ERα-Negative and Triple-Negative
Breast Cancers. We and others previously reported the
inverse relationship between PKCα and ERα expression
[12, 26, 27]. Upon stratiﬁcation by race (Table 3(a)), the
intensity of PKCα expression achieves statistical signiﬁcance
in the African American patients, whereas the frequency of
expression does not. Conversely in the Caucasian patients,
PKCα frequency of expression achieves statistical signiﬁ-
cance, whereas intensity of staining does not. The composite
score as determined by the sum of frequency and intensity
achieves statistical signiﬁcance only in the African American
population. When Caucasian and African American patient
populations are combined, there is a statistically signiﬁcant
inverse relationship between PKCα and ERα frequency and
intensity of expression (Table 3(b)).
We next examined PKCα expression stratiﬁed by breast
cancer subtype categorized as luminal A (ERα+/PR+/
Her2−),luminalB(ERα+/PR+/Her2+),HER2(ERα−/PR−/
Her2+), and triple-negative breast cancer (TNBC, ERα−/
PR−/Her2−) based solely on receptor expression as deter-
mined by IHC. There is a strong association of PKCα ex-
pression and breast cancer subtypes (P<0.001) that
is maintained when stratiﬁed by race (see supplemental4 International Journal of Breast Cancer
PKCα low frequency (40x) PKCα low intensity (40x) PKCα high frequency and intensity (40x)
(a)
ERβ cytoplasmic (40x) ERβ nuclear high frequency (40x) ERβ nuclear low frequency (40x)
(b)
Figure 1: (a) Expression of PKCα (brown immunoperoxidase stain, blue hematoxylin counterstain). (b) Expression of ERβ (brown
immunoperoxidase stain, blue hematoxylin counterstain).
Table 2: (a) PKCα expression is similar in African American and
Caucasian patients. (b) ERβ expression and subcellular localization
is similar in African American and Caucasian patients.
(a)
Outcome
Median (minimum, maximum)
P value∗
AA Caucasian
PKCα (freq) 2 (0,4) 2 (0,4) 0.46
PKCα (int) 2 (0,4) 1 (0,4) 0.52
PKCα (sum) 4 (0,8) 4 (0,8) 0.49
∗P value based on the Wilcoxon rank-(sum) test.
(b)
Outcome
Median (minimum, maximum)
P value∗
AA Caucasian
ERβ freq(n) 2 (0, 4) 2 (0, 4) 1.00
ERβ int (n) 1 (0, 4) 1 (0, 4) 0.76
ERβ freq (c) 3 (1, 4) 3 (2, 4) 0.83
ERβ int (c) 1 (1, 3) 1 (1, 4) 0.84
∗P value based on Wilcoxon rank-Sum test. n: nuclear; c: cytoplasmic.
Tables 1(a) and 1(b) in Supplementary Material available
online at doi:10.155/2012/740353). Since the incidence of
TNBC is higher in African American patients compared
to Caucasian patients, we asked whether PKCα expression
is associated with TNBCs. Combining all patients we ﬁnd
as t r o n ga s s o c i a t i o no fP K C α expression with the TNBC
s u b t y p ec o m p a r e dt oa l lo t h e rs u b t y p e s( Table 4(a)). When
stratiﬁed by race, frequency of PKCα expression but not
intensity is similarly associated with the TNBC subtype in
African American and Caucasian patients (Table 4(b)).
TodeterminewhetherTNBCisanindependentpredictor
of PKCα, we performed general regression analysis with
adjustment for tumor grade, patient age, lymph node status,
and tumor size and found that the frequency and intensity
of PKCα expression no longer correlates with TNBC (freq,
P = 0.262; int, P = 0.957). This prompted us to ask
whether PKCα expression correlates with the other known
independent predictors of TNBC (tumor grade, patient
age, lymph node status, and tumor size). Combining all
patients, we ﬁnd that grade 3 tumors have the highest
frequency and intensity of PKCα expression (Table 5(a));
however there is no correlation of PKCα with patient age,
tumor size, or lymph node status. Interestingly, when the
patients are stratiﬁed by race, the positive relationship of
PKCα and tumor grade is statistically signiﬁcant only in
the African American patients, but not in tumors from
Caucasian patients (Table 5(b)).
In our population of TNBC cases, we found a statistically
signiﬁcant correlation with tumor grade (P<0.0001),
patientage(P = 0.002),andtumorsize(P = 0.004);however
thereisnocorrelationbetweenTNBCandlymphnodestatus
(P = 0.1334).
3.3. ERβ Expression and Localization in Triple-Negative
Tumors. Since both expression and subcellular localization
of ERβ are reported to inﬂuence clinical outcome andInternational Journal of Breast Cancer 5
Table 3: (a) Relationship of ERα status and PKCα expression based on race. (b) ERα status and PKCα expression is inversely related.
(a)
Race Outcome
Median (minimum, maximum)
P value∗
ER(−)
(N = 80)
ER(+)
(N = 118)
PKC (freq) 2 (0, 4) 2 (0, 4) 0.09
AA PKC (int) 2 (0, 4) 1 (0, 4) 0.01††
PKC (sum) 5 (0, 8) 4 (0, 8) 0.02†
PKC (freq) 3 (0, 4) 2 (0, 4) 0.02†
Caucasian PKC (int) 1.5 (0, 4) 1 (0, 4) 0.38
PKC (sum) 4.5 (0, 8) 3 (0, 7) 0.07
∗P value based on the Wilcoxon Rank (sum) Test. †P value <0.05; ††P value <0.01.
(b)
Outcome
Median (minimum, maximum)
P value∗
ER(−) ER(+)
PKCα (freq) 3 (0, 4) 2 (0, 4) 0.004††
PKCα (int) 2 (0, 4) 1 (0, 4) 0.012†
PKCα (sum) 5 (0, 8) 3 (0, 8) 0.002††
∗P value based on the Wilcoxon Rank (sum) Test. †P value <0.05; ††P value <0.01.
Table 4: (a) PKCα expression is higher in triple-negative breast cancers compared to other subtypes. (b) Correlation of PKCα expression
and triple-negative breast cancer is similar in African American and Caucasian patients.
(a)
Outcome
Median (minimum, maximum)
P value∗
TNBC
(N = 45)
All other subtypes
(N = 153)
PKCα (freq) 3 (0, 4) 2 (0, 4) 0.001†††
PKCα (int) 2 (0, 4) 1 (0, 4) 0.010†
PKCα (sum) 5 (0, 8) 4 (0, 8) 0.001†††
∗P value based on the Wilcoxon Rank-(sum) test. †P value <0.05; ††P value <0.01; †††P value
<0.001.
(b)
Race Outcome
Median (minimum, maximum)
P value∗
TNBC
(N = 45)
All other subtypes
(N = 153)
AA
(N = 105)
PKC (freq) 3 (0, 4) 2 (0, 4) 0.019†
PKC (int) 2 (0, 4) 1 (0, 4) 0.061
PKC (sum) 5 (0, 8) 4 (0, 8) 0.014†
Caucasian
(N = 93)
PKC (freq) 3 (0, 4) 2 (0, 4) 0.010††
PKC (int) 2 (0, 3) 1 (0, 4) 0.087
PKC (sum) 5 (0, 7) 3 (0, 8) 0.018†
∗P value based on the Wilcoxon Rank-(sum) test. †P value <0.05; ††P value <0.01.
response to therapy, we examined whether ERβ is diﬀer-
entially expressed in the various breast cancer subtypes.
Upon stratiﬁcation of all patients by subtype as previously
categorized, we ﬁnd there is no association of ERβ with
any particular subtype (supplemental Table 2). However
when we compared TNBC to all other subtypes, we ﬁnd
that nuclear ERβ expression is lower in TNBC compared
to all other subtypes (Table 6). Interestingly when patients
are stratiﬁed by age (<50yrs versus ≥50yrs), the inverse
relationship of nuclear ERβ with TNBC is statistically
signiﬁcant only in the younger patients (freq, P = 0.021),
whereas when stratiﬁed by race, statistical signiﬁcance is6 International Journal of Breast Cancer
Table 5:(a)HightumorgradecorrelateswithelevatedPKCαexpression.(b)PKCαandtumorgradeiscorrelativeinAAbutnotinCaucasian
patients.
(a)
Outcome
Median (minimum, maximum)
P value∗
Grade = 1
(N = 12)
Grade = 2
(N = 42)
Grade = 3
(N = 65)
PKCα (freq) 0.50 (0, 3) 2.00 (0, 4) 3.00 (0, 4) 0.010††
PKCα (int) 0.50 (0, 3) 1.00 (0, 3) 2.00 (0, 4) 0.012†
PKCα (sum) 1.00 (0, 6) 3.50 (0, 7) 5.00 (0, 8) 0.004††
∗P value is based on the Kruskal-Wallis Test. †P value <0.05; ††P value <0.01.
(b)
Race Outcome
Median (minimum, maximum)
P value∗
Grade=1
(N = 6)
Grade=3
(N = 46)
PKCα (freq) 0 (0, 1) 2 (0, 3) 2 (0, 4) 0.007††
AA
(N = 73) PKCα (int)) 0 (0, 3) 1 (0, 3) 2 (0, 3) 0.017†
PKCα (sum) 0 (0, 4) 3 (0, 5) 5 (0, 7) 0.003††
Grade = 1
(N = 6)
Grade = 2
(N = 21)
Grade = 3
(N = 19)
PKCα (freq) 2.5 (0, 3) 2 (0, 4) 3 (0, 4) 0.248
Caucasian
(N = 46) PKCα (int) 1.5 (0, 3) 2 (0, 3) 2 (0, 4) 0.277
PKCα (sum) 4.0 (0, 6) 4 (0, 7) 5 (0, 8) 0.169
∗P value is based on the Kruskal-Wallis Test. †P value <0.05; ††P value < 0.01.
Table 6: Nuclear ERβ expression is lower in triple-negative patients.
Outcome
Median (minimum, maximum)
P value∗
TNBC
(N = 45)
All other subtypes
(N = 153)
ERβ (freq) (n) 0 (0, 4) 2 (0, 4) 0.022†
ERβ (int) (n) 0 (0, 4) 1 (0, 4) 0.024†
ERβ (freq) (c) 3 (1, 3) 3 (2, 4) 0.079
ERβ (int) (c) 1 (1, 3) 1 (1, 4) 0.378
∗P value is based on the Wilcoxon Rank-(sum) test. n: nuclear; c: cytoplasmic;
†P value < 0.05.
achieved only in Caucasian patients (freq, P = 0.023; int,
P = 0.015) (results not shown). No association between ERβ
and tumor grade was found.
4. Discussion
This is the ﬁrst report to our knowledge to examine
PKCα and ERβ protein expression using IHC compar-
ing breast cancers from Caucasian and African American
patients. We chose to examine the expression of these two
biomarkers since both are known to be associated with
endocrine response and African American patients have a
higher incidence of endocrine-resistant breast cancer. PKCα
expression is inversely related to ERα status [12, 13, 27],
associated with more aggressive breast cancers [13]a n d
endocrine resistance [11, 12]. Although there is less clarity
regarding the clinical relevance of ERβ, with the availability
of more reliable ERβ antibodies, the current consensus is
that ERβ expression is associated with better prognosis [28],
whereas cytoplasmic localization of the ERβ2 isoform may
indicate worse prognosis [17]. Earlier studies that utilized
ERβ mRNA expression in breast cancers yielded conﬂicting
ﬁndings correlating ERβ expression with good prognosis
while others report association with poor prognosis [29, 30].
Although we ﬁnd no diﬀerence in the expression level of
PKCα and ERβ comparing the two races, we ﬁnd a highly
signiﬁcant association of PKCα with TNBCs (Table 4(a)).
Multivariate analysis revealed that the association of PKCα
expression with higher tumor grade is likely to account for
the signiﬁcant association of PKCα with TNBC since PKCαInternational Journal of Breast Cancer 7
does not correlate with patient age, tumor size, or lymph
node status.
The African American patients in this study exhibit a
higherincidenceofTNBC(28%versus18%)andmoregrade
3 tumors (63% versus 41%) (Table 1). This is an intriguing
ﬁnding that presents a potential therapeutic opportunity
since there are few treatment options available for this
aggressivebreastcancersubtype.PKCαwastargetedinbreast
cancer patients using the antisense compound Aﬃnitak
[31]; however since the patients were not preselected for
high tumor PKCα expression, the response to treatment
was modest. We speculate that preselection of patients with
TNBC with high-grade tumors in addition to elevated PKCα
expression may improve the response rate to a PKCα-
directed therapy. Another potential therapeutic approach
may be to revisit the administration of estradiol treatment
[32, 33]. Prior to the introduction of tamoxifen, high dose
estrogen and diethylstilbestrol (DES) was used to treat breast
cancers with similar response rates as tamoxifen, but with
greater side eﬀects [32, 34]. A recent phase 2 randomized
trial was conducted comparing 2 doses of estrogen (6mg
and 30mg) in patients with metastatic disease resistant to
aromatase inhibitor therapy [35]. The majority of these
patients were ERα positive and the clinical beneﬁt rate of 28-
29% was similar between the two dosing regimens, whereas
the number of adverse events was much lower with the 6mg
estrogen dose. With the completion of this phase 2 study, we
proposethatthe6mgestrogendosebetestedinpatientswith
PKCα-overexpressing TNBCs. In our T47D/PKCα xenograft
preclinical model, we reported complete tumor regression
following 17β-estradiol (E2) administration [36]a n ds u b -
sequently determined that ERα is likely to be required for
E2-triggeredtumorregression.Interestingly,ourpreliminary
studies suggest that it is extranuclear and not nuclear ERα
that may be most important for mediating the inhibitory
signal[37].TNBCsbydeﬁnitiondonot express nuclearERα;
however pathologists do not routinely score extranuclear
ERα since optimal clinical IHC methods for detection of
extranuclear or membrane ERα have not yet been developed.
It is possible that a subset of TNBCs may in fact express
extranuclear ERα. With the recent focus on the clinical
signiﬁcance of membrane and extranuclear ERα,d e t e c t i o n
methods for clinical use are likely to soon become available
[38]. We propose further investigation is warranted to
determine whether the PKCα/extranuclear ERα pathway is a
feasible therapeutic target in TNBCs.
The ﬁrst study to address the role of ERβ expression
and racial disparity reported a greater decrease in the
protectiveERβinbreastcancersinAfricanAmericanpatients
compared with their matched adjacent normal tissue than
levels found in Caucasian patients [39]. In a follow-up
study using isoform-speciﬁc ERβ primer-probe pairs, these
investigators reported higher ERβ isoform expression in
ERα-negative breast cancers in African American patients
than in Caucasian patients [40]. This ﬁnding is in agree-
ment with our results that African American patients have
a higher percentage of ERα-negative/ERβ-positive breast
cancers (Table 1, Caucasian, 17% ERα−/ERβ+, African
American, 30% ERα−/ERβ+). Interestingly patients with
ERα-negative/ERβ-positive breast cancers are associated
with increased survival compared to patients with ERα-
negative/ERβ-negative breast cancers [41], suggesting that
these ERα-negative patients would beneﬁt from tamoxifen
treatment. Although we hypothesized that African American
patients would have higher cytoplasmic ERβ expression,
in fact we ﬁnd no diﬀerence in the level of cytoplasmic
ERβ comparing the two races (Table 2(b)). However 29%
of African American patients exhibit both nuclear and
cytoplasmic ERβ expression whereas only 11% of Caucasian
patients express ERβ in both subcellular locations (Table 1).
The ﬁnding that nuclear ERβ is not associated with TNBC
supports the observation that nuclear localization of ERβ is
associated with better prognosis (Table 6(b)). However, since
the 14C8 antibody recognizes all isoforms of ERβ,i ti sn o t
possible to determine the speciﬁc presence and localization
of ERβ2, the isoform reported to be associated with worse
prognosis when localized to the cytoplasm [17]. Therefore,
the signiﬁcance of the subcellular distribution of ERβ with
respect to prognosis cannot be determined in our study.
For the ﬁrst time this study examined the association
of two potential prognostic biomarkers, PKCα and ERβ,
comparing African American and Caucasian patient popula-
tions. A signiﬁcant limitation of our study is that we did not
have access to treatment or follow-up information on these
patients; therefore it was not possible to determine whether
these biomarkers are associated with response to therapy,
time to progression, or overall survival. Further investigation
is warranted to determine the utility of PKCα as a potential
therapeutic target and ERβ as a potential biomarker for
tamoxifen therapy in ERα-negative and TNBCs in patients
of all races.
5. Conclusions
Our ﬁndings suggest that PKCα is a potential therapeutic
targetforthetreatmentofERα-negativedisease,TNBCs,and
high-grade tumors. Whereas lack of nuclear ERβ in TNBCs
may be a biomarker of poor prognosis, further investigation
is warranted to determine the signiﬁcance of ERβ subcellular
localization. While TNBCs occur more frequently in African
American patients, all patients that present with this breast
cancer subtype may beneﬁt from the clinical application of
these biomarkers. Further investigation into these potential
therapeutic and prognostic approaches is warranted.
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